Navigation Links
ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
Date:3/11/2011

ADDISON, Texas, March 11, 2011 /PRNewswire/ -- ULURUInc.(NYSE Amex: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today reported that it has received notice from NYSE Amex LLC (the "Exchange") advising ULURU that it is not in compliance with a certain condition of the Exchange's continued listing standards under Section 1003 of the Exchange's Company Guide (the "Company Guide").

In a letter to ULURU, the Exchange stated that it is concerned that ULURU's common stock, as a result of its low selling price, may not be suitable for auction market trading.  Therefore, pursuant to Section 1003(f)(v) of the Company Guide, ULURU's continued listing is predicated on it effecting a reverse stock split of its common stock by no later than June 7, 2011.  As a result of the foregoing, ULURU has become subject to the procedures and requirements of Section 1009 of the Company Guide.

ULURU intends to satisfy the Exchange's continued listing standards by presenting a proposal and resolution to be approved by its shareholders, to effect a reverse stock split of ULURU's common stock, at ULURU's next annual meeting of shareholders to be held no later than June 1, 2011.

AboutULURUInc.:ULURUInc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's compliance with the continued listing standards of the NYSE Amex, to the risk that a reverse stock split may not result in an actual increase in the market price of our common stock, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. GrayPresident&CEOTerry K. WallbergVice President & CFO(214) 905-5145
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
2. ULURU Inc. to Raise $500,000 in Registered Direct Offering
3. ULURU Inc. Reports Third Quarter 2010 Financial Results
4. ULURU Inc. Provides Altrazeal® Clinical Update
5. ULURU Inc. Announces Conference Call
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
8. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
10. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
Breaking Medicine Technology:
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... ProElectric ... Final Cut Pro X. Pick and choose from a variety of electric styles including ... color swabs. Users can customize shadow, dof blur, three dimensional rotation, and much more. ...
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, ... by partnering with college students at University of Colorado in Boulder to create ... advertising campaigns class in the School of Journalism, who selected Beanfields as the ...
(Date:5/2/2016)... , ... May 02, 2016 , ... “Engineering Bubbles,” an ... at the 2016 ARRS Art Forum held recently at the Annual Meeting in Los ... expression among ARRS members and Annual Meeting attendees. , “Through art ...
(Date:5/2/2016)... ... , ... Dr. Philip Shindler, dentist in Agoura Hills , now offers ... many necessary dental treatments could require multiple appointments to complete. This could mean taking ... time. Not only could this be inconvenient, but it could also be overwhelmingly unpleasant ...
(Date:5/2/2016)... ... May 02, 2016 , ... This week Omega Institute, a premier ... season which runs through October. Omega is offering a record 370 in-person workshops and ... has never been such widespread interest in or need for the knowledge and skills ...
Breaking Medicine News(10 mins):